Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy ...
Nov 30, 2017
0
205
(HealthDay)—In patients with progressive glioblastoma, treatment with lomustine plus bevacizumab does not confer a survival advantage over treatment with lomustine alone, according to a study published online Nov. 15 in ...
Nov 17, 2017
0
0
(HealthDay)—HIV-positive individuals treated with combination antiretroviral therapy (cART) have poorer neuropsychological test scores than controls but no significant neuropsychological decline over time, according to ...
Nov 15, 2017
0
1
(HealthDay)—For patients with inflammatory bowel disease (IBD), the risk of lymphoma is increased with use of thiopurine monotherapy, anti-tumor necrosis factor (TNF) monotherapy, and combination therapy, according to a ...
Nov 8, 2017
0
0
A combination of two antibiotics is often prescribed to treat community-acquired pneumonia in children but a JAMA Pediatrics study is now showing that using just one of the two has the same benefit to patients in most cases.
Nov 1, 2017
0
0
(HealthDay)—Combination therapy consisting of ranibizumab plus verteporfin photodynamic therapy (vPDT) is superior to ranibizumab monotherapy for treatment of eyes with polypoidal choroidal vasculopathy (PCV), according ...
Oct 9, 2017
0
0
(HealthDay)—For hospitalized children, coadministration of intravenous (IV) vancomycin and piperacillin/tazobactam is associated with increased risk of acute kidney injury (AKI), according to a study published online Oct. ...
Oct 3, 2017
0
0
(HealthDay)—Patients receiving immune checkpoint inhibitor (ICI) regimens may experience endocrine dysfunction, with increased risk of thyroid dysfunction and hypophysitis for patients on combination therapy, according ...
Sep 29, 2017
0
1
New recommendations on antiretroviral drugs for pregnant women living with HIV can help women make more informed choices about benefits and harms, say a panel of international experts in The BMJ today.
Sep 11, 2017
0
3
Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented today ...
Sep 11, 2017
0
0
